The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Allergan; AstraZeneca Japan; Chugai Pharma; Elsevier Japan; Novartis Pharmaceuticals UK Ltd.
Research Funding - AstraZeneca Japan
Risk factors of ipsilateral breast tumor recurrence in triple-negative or HER2-positive breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy.
 
Mizuho Tazo
No Relationships to Disclose
 
Yasuyuki Kojima
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst)
 
Atsushi Yoshida
Honoraria - Chugai Pharma; Pfizer
 
Sayuka Nakayama
No Relationships to Disclose
 
Ryu Tokui
No Relationships to Disclose
 
Tomoko Ogawa
No Relationships to Disclose
 
Takashi Kuwayama
Honoraria - Chugai Pharma; Eisai; Maruho; Taiho Pharmaceutical
 
Takahiro Nakayama
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Taiho Pharmaceutical; Takeda
 
Hideko Yamauchi
No Relationships to Disclose
 
Koichiro Tsugawa
No Relationships to Disclose
 
Seigo Nakamura
Honoraria - AstraZeneca Japan; Chugai Pharma
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Konica Minolta (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Naoki Hayashi
Honoraria - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Devicor Medical Products; Kiowa Kirin; Lilly; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly; Pfizer
 
Makoto Ishitobi
No Relationships to Disclose